Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population

Annals of Clinical Biochemistry

Volumn 54, Issue 1, 2017, Pages 86-91

  Suehiro, Yutaka ^a   Sakai, Kouhei ^a   Nishioka, Mitsuaki ^b   Hashimoto, Shinichi ^a   Takami, Taro ^a   Higaki, Shingo ^c   Shindo, Yoshitaro ^a   Hazama, Shoichi ^a   Oka, Masaaki ^a   Nagano, Hiroaki ^a   Sakaida, Isao ^b   Yamasaki, Takahiro ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^c Sentohiru Hospital   (Japan)

Author keywords

Colorectal cancer; DNA test; droplet digital PCR; Fusobacterium nucleatum; stool

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PRACTICE; COLORECTAL NONADVANCED ADENOMA; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FECES ANALYSIS; FEMALE; FUSOBACTERIUM NUCLEATUM; GENE DOSAGE; HUMAN; JAPANESE (PEOPLE); MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOOL DNA TESTING; ADENOMA; CANCER GRADING; CARCINOMA IN SITU; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; COMPLICATION; COPY NUMBER VARIATION; FECES; FUSOBACTERIUM INFECTIONS; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

BACTERIAL DNA; TUMOR MARKER;

ADENOMA; ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA IN SITU; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA, BACTERIAL; FECES; FEMALE; FUSOBACTERIUM INFECTIONS; FUSOBACTERIUM NUCLEATUM; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; ROC CURVE;

EID: 85006832799     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563216643970     Document Type: Article

References (37)

1. Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2. Pawa N, Arulampalam T, Norton JD. Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol 2011; 8: 711–722.
3. Di Lena M, Travaglio E, Altomare DF. New strategies for colorectal cancer screening. World J Gastroenterol 2013; 19: 1855–1860.
4. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315: 157–168.
5. van Turenhout ST, Oort FA, Terhaar sive Droste JS. Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results. Gastrointest Endosc 2012; 76: 136–143.
6. van Rossum LG, van Rijn AF, Laheij RJ. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82–90.
7. Velez JP, Schwesinger WH, Stauffer J. Bidirectional endoscopy in patients with fecal occult blood. Surg Endosc 2002; 16: 117–120.
8. Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis 2013; 34: 2193–2197.
9. Michaud DS, Izard J, Wilhelm-Benartzi CS. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 2013; 62: 1764–1770.
10. Signat B, Roques C, Poulet P. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol 2011; 13: 25–36.
11. Ohkusa T, Okayasu I, Ogihara T. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79–83.
12. Minami M, Ando T, Okamoto A. Seroprevalence of Fusobacterium varium in ulcerative colitis patients in Japan. FEMS Immunol Med Microbiol 2009; 56: 67–72.
13. Strauss J, Kaplan GG, Beck PL. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 2011; 17: 1971–1978.
14. Brook I, Frazier EH. Microbiological analysis of pancreatic abscess. Clin Infect Dis 1996; 22: 384–385.
15. Shahani L, Khardori N. Fusobacterium necrophorum – beyond Lemierres syndrome. BMJ Case Rep 2011; 2011: bcr0720114527–bcr0720114527.
16. Yoneda M, Kato S, Mawatari H. Liver abscess caused by periodontal bacterial infection with Fusobacterium necrophorum. Hepatol Res 2011; 41: 194–196.
17. Athavale NV, Leitch DG, Cowling P. Liver abscesses due to Fusobacterium spp. that mimick malignant metastatic liver disease. Eur J Clin Microbiol Infect Dis 2002; 21: 884–886.
18. Kostic AD, Gevers D, Pedamallu CS. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292–298.
19. Castellarin M, Warren RL, Freeman JD. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299–306.
20. Tahara T, Yamamoto E, Suzuki H. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014; 74: 1311–1318.
21. Flanagan L, Schmid J, Ebert M. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014; 33: 1381–1390.
22. Kostic AD, Chun E, Robertson L. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14: 207–215.
23. Rubinstein MR, Wang X, Liu W. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14: 195–206.
24. Chen W, Liu F, Ling Z. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012; 7: e39743–e39743.
25. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370: 1287–1297.
26. Sobin LH, Gospodarowicz MK and Wittekind C (eds). TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell, 2009
27. Martin FE, Nadkarni MA, Jacques NA. Quantitative microbiological study of human carious dentine by culture and real-time PCR: association of anaerobes with histopathological changes in chronic pulpitis. J Clin Microbiol 2002; 40: 1698–1704.
28. Hindson BJ, Ness KD, Masquelier DA. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83: 8604–8610.
29. Wang N, Guo B and Liu Y. Methods and materials for quantification of Fusobacterium nucleatum DNA in stool to diagnose colorectal neoplasm. Patent application 20140024036, USA, 2014
30. Konishi K, Shen L, Wang S. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 2007; 132: 1254–1260.
31. Issa JP, Ahuja N, Toyota M. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 3573–3577.
32. Kusano M, Toyota M, Suzuki H. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006; 106: 1467–1479.
33. Nishikawa J, Yoshiyama H, Iizasa H. Epstein-barr virus in gastric carcinoma. Cancers (Basel) 2014; 6: 2259–2274.
34. Okada T, Nakamura M, Nishikawa J. Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas. Cancer Sci 2013; 104: 1309–1314.
35. Saito M, Nishikawa J, Okada T. Role of DNA methylation in the development of Epstein-Barr virus-associated gastric carcinoma. J Med Virol 2013; 85: 121–127.
36. Shen L, Toyota M, Kondo Y. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654–18659.
37. Ahn JB, Chung WB, Maeda O. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011; 117: 1847–1854.